The folks over at FPA Patent Attorneys posted a nice article on Patents directed to deuterium-modified drugs.
Check it out by clicking below:
“He Ain’t Heavy, He’s My Brother” – Patents Directed to Deuterium Modified Drugs
The folks over at FPA Patent Attorneys posted a nice article on Patents directed to deuterium-modified drugs.
Check it out by clicking below:
“He Ain’t Heavy, He’s My Brother” – Patents Directed to Deuterium Modified Drugs
Check out the USPTO’s Patents Ombudsman program:
The USPTO, provides an example of a patent-eligible claim for a process of hydrolyzing fat molecules into free fatty acids and glycerol without using conventional methods (at the time of invention) of steam distillation with lye or sulfuric acid. [May, 2016]
May 2016 Update: Subject Matter Eligibility Examples: Life Sciences (May 6, 2016)
The USPTO based the following “patent eligible” claim on technology from US Patent 11,766, which was upheld by the Supreme Court in Tilghman v. Proctor, 102 U.S. 707 (1881). Although the case is very old, the USPTO notes that Supreme Court has subsequently described the decision as upholding the eligibility of process claims containing a law of nature. See, e.g., Parker v. Flook, 437 U.S. 584, 590-91 and n.12 (1978); Gottschalk v. Benson, 409 U.S. 63, 70 (1972).
Claim 1. A process for obtaining free fatty acids and glycerol from fat comprising:
(a) mixing substantially equal quantities of fat and water in a closed vessel; and
(b) heating the mixture to an elevated temperature of at least 600 degrees Fahrenheit under sufficient pressure to prevent the formation of steam in the closed vessel; and maintaining the elevated temperature for at least 10 minutes.
Although the claim is founded upon a chemical principle relating to neutral fats, the claim is eligible because, it is not attempting to tie up the chemical principal so that others cannot practice it. Even if the claim were directed to a judicial exception, the claim amounts to something “significantly more” than any exception. The claim would amount to something “significantly more” because the claim recites specific unconventional steps.
Chemical & Engineering News (C&EN) published a news update about a 57% increase in patent activity over the past 5 years for fighting fungal wilt known as Panama disease. Chemical Abstracts Service searched the HCAplus database on STN with a result of 510 patents since 2010 that mention Fusarium oxysporum. C&EN notes that Azole-based fungicides continue to dominate the fight and included BASF patent application publication WO 2015/181009 as an example.
“New Weapons in the Fight against Fungal Wilt”
Chemical & Engineering News, Vol. 44, page 11, November 7, 2016.
http://cen.acs.org/articles/94/i43/New-weapons-fight-against-fungal.html
The United States Patent and Trademark Office (USPTO) published a proposed rule for recognizing privileged communications between clients and non-attorney patent agents and forgein patent practitioners at the Patent Trial and Appeal Board (PTAB).
This new rule, however, will not affect the duty of disclosure and candor before the Office under 37 CFR 1.56.
The Office is soliciting comments from the public on this proposed rulemaking. Written comments must be received on or before December 19, 2016 to ensure consideration.
I created this site on August 27, 2016. Please Join me as I build it into a resource for organic chemistry patents.